Health
Abbott Bumps Up Forecast as Device Sales Boost Quarter
- Medical device gains helped by Lingo glucose monitors
- Investors remain concerned about formula litigation risk
The Abbott Laboratories headquarters in Abbott Park, Illinois.
Photographer: Christopher Dilts/BloombergThis article is for subscribers only.
Abbott Laboratories nudged up its full-year profit guidance as strong growth in its medical-devices segment helped quarterly results beat estimates.
Adjusted earnings for 2024 will be from $4.61 to $4.71 a share, the company said Thursday, a slight increase from the earlier range of $4.55 to $4.70 a share. Medical device sales grew 12% led by strong performance for the company’s Libre blood glucose monitor.